The ESSENCE-2 study showed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score.
Investigators led by Esen Akpek, MD, from the Wilmer Eye Institute, The Johns Hopkins University, Baltimore, and colleagues reported the clinically meaningful results of the use of water-free topical cyclosporine 0.1% solution to treat patients with moderate to severe dry eye disease (DED). The study group observed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score compared with the vehicle.1
A treatment that both provides rapid onset of action and is well tolerated would fill an important gap in this patient population, the investigators pointed out.
The ESSENCE-2 study was a randomized, double-masked, vehicle-controlled, clinical trial that assessed the efficacy, safety, and tolerability of a water-free cyclosporine ophthalmic solution, 0.1% (CyclASol, Novaliq GmbH). The study included 834 patients with moderate to severe DED who were randomized to active treatment (n=423) or vehicle (n=411) following a 14-day run-in period during which they instilled an artificial tear twice daily. The patients instilled either cyclosporine or vehicle twice daily for 29 days and the results were compared.
The study period ran from December 5, 2020, to October 8, 2021, at US 27 sites. The primary endpoints were the changes in the tCFS (0-15 [best to worst] on the National Eye Institute scale) and in the dryness score (0-100 [best to worst] on the visual analog scale) at day 29 compared with baseline. The investigators also evaluated the conjunctival staining, central corneal fluorescein staining, and the tCFS responders.
The patients were a mean age of 57.1 years and almost three-quarters were women.
Participants were a mean age of 57.1 years, and 609 (73.0%) were female.
The authors reported the instillation of cyclosporine provided a greater improvement in the tCFS compared with the vehicle, ie, −4.0 grades versus −3.6 grades, respectively, at day 29, a difference that reached significance (P =0 .03). The dryness score improved compared with baseline in both groups, ie, −12.2 points for cyclosporine and −13.6 points for vehicle; the difference between the groups was not significant (P=0 .38).
“In the cyclosporine group, 293 participants (71.6%) achieved clinically meaningful reductions of 3 grades or higher in tCFS vs 236 participants (59.7%) in the vehicle group (change, 12.6%; 95% confidence interval [CI], 6.0%-19.3%; P < 0.001). These responders showed greater improvement in symptoms at day 29, including dryness (change, −4.6; 95% CI, −8.0 to −1.2; P = 0.007) and blurred vision (change, −3.5; 95% CI, −6.6 to −4.0; P =0 .03), compared with non-responders,” the investigators reported.
An important take-away point of the study was that the total and central corneal staining score showed improvements after only 2 weeks of treatment, with persistent efficacy through day 29. The rapid onset and magnitude of improvements of the corneal epithelial damage are potential differentiators to existing therapies, the authors emphasized.